Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis

SUMMARY: Invasive fungal infections (IFI) are common in allogeneic SCT recipients. We have reviewed our experience of IFI with special reference to candidaemia in 685 adult patients

transplanted in 1983–2002. The donor was a matched sibling in 505 patients and an unrelated donor in 180 patients. A BM graft was used in 561 patients and a PB graft in 124 patients.

Fluconazole prophylaxis was not used during the study period. Definite or probable IFI was observed in 60 patients (8.7%) with a dominance of _Aspergillus_ infections (46 patients, incidence

6.7%). Candidaemia was found only in nine patients (1.3%). The causative agents were _Candida albicans_ (_n_=8), _C. krusei_ (_n_=2), and _C. glabrata_ (_n_=1); in two patients, two

causative agents were found. The median time to the diagnosis of candidaemia was 53 days (range 6–249 days) post transplant. Seven patients were neutropaenic at diagnosis, and four patients

had experienced acute GVHD. All patients received antifungal therapy, but only one patient was cured. According to this study, candidaemia was a rare event in allogeneic SCT recipients.

Thus, systematic prophylaxis against _Candida_ infections might not be indicated. The prognosis of established infections is still poor due to comorbid conditions, notably GVHD. Access

through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal

Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices

may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

SIMILAR CONTENT BEING VIEWED BY OTHERS RISK STRATIFICATION AND IMPACT OF DONOR TYPE ON BREAKTHROUGH INVASIVE FUNGAL INFECTIONS IN HAEMATOPOIETIC CELL TRANSPLANT WITH POST-TRANSPLANT

CYCLOPHOSPHAMIDE AND MOULD-ACTIVE PROPHYLAXIS Article 23 April 2025 INFECTIOUS COMPLICATIONS AFTER SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULT PATIENTS WITH HEMATOLOGICAL

MALIGNANCIES Article 23 September 2022 PRIMARY ANTIFUNGAL PROPHYLAXIS IN HEMATOLOGICAL MALIGNANCIES. UPDATED CLINICAL PRACTICE GUIDELINES BY THE EUROPEAN CONFERENCE ON INFECTIONS IN LEUKEMIA

(ECIL) Article Open access 09 April 2025 REFERENCES * Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. _Bone

Marrow Transplant_ 1997; 19: 801–808. Article  CAS  Google Scholar  * Martino R, Subina M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell

transplantation: incidence and risk factors in 395 patients. _Br J Haematol_ 2002; 116: 475–482. Article  Google Scholar  * Morrison VA, Haake RJ, Weisdorf DJ . Non-_Candida_ fungal

infections after bone marrow transplantation: risk factors and outcome. _Am J Med_ 1994; 96: 497–503. Article  CAS  Google Scholar  * Marr KA, Carter RA, Boekh M et al. Invasive

aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. _Blood_ 2002; 100: 4358–4366. Article  CAS  Google Scholar  * Verfaillie C, Weisdorf D,

Haake R et al. _Candida_ infections in bone marrow transplant recipients. _Bone Marrow Transplant_ 1991; 8: 177–184. CAS  Google Scholar  * Goodrich JM, Reed EC, Mori M et al. Clinical

features and analysis of risk factors for invasive candidal infection after marrow transplantation. _J Infect Dis_ 1991; 164: 731–740. Article  CAS  Google Scholar  * Safdar A, van Rhee F,

Henslee-Downey JP et al. _Candida glabrata_ and _Candida krusei_ fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on

incidence and outcome. _Bone Marrow Transplant_ 2001; 28: 873–878. Article  CAS  Google Scholar  * Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent

fungal infections in patients undergoing bone marrow transplantation. _N Engl J Med_ 1992; 326: 845–851. Article  CAS  Google Scholar  * Slavin MA, Osborne B, Adams R et al. Efficacy and

safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. _J Infect Dis_ 1995; 171: 1545–1552. Article  CAS 

Google Scholar  * Marr K, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candiasis-related death in allogeneic marrow

transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. _Blood_ 2000; 96: 2055–2061. CAS  Google Scholar  * Ringden O, Remberger M, Ruutu T, _et al_, for the

Nordic Bone Marrow Transplantation Group. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan _versus_ total body irradiation:

long-term results of a randomized trial in allogeneic marrow recipients with leukemia. _Blood_ 1999; 93: 2196–2201. CAS  Google Scholar  * Ruutu T, Volin L, Parkkali T et al. Cyclosporine,

methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA identical sibling

donor: a prospective randomized study. _Blood_ 2000; 96: 2391–2398. CAS  Google Scholar  * Marr KA, Seidel K, White TC, Bowden RA . Candidemia in allogeneic blood and marrow transplant

recipients: evolution of risk factors after the adoption of prophylactic fluconazole. _J Infect Dis_ 2000; 181: 309–316. Article  CAS  Google Scholar  * Jantunen E, Salonen J, Juvonen E et

al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. _Eur J Haematol_ 2004; 73: 174–178. Article  CAS  Google

Scholar  * Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. _Clin Infect Dis_ 1999; 29: 239–244. Article  CAS 

Google Scholar  * Poikonen E, Lyytikäinen O, Anttila V-J, Ruutu P . Candidemia in Finland, 1995–1999. _Emerg Infect Dis_ 2003; 9: 985–990. Article  Google Scholar  * Wingard JR . Fungal

infections after bone marrow transplant. _Biol Blood Marrow Transplant_ 1999; 5: 55–68. Article  CAS  Google Scholar  * de la Rosa GR, Champlin RE, Kontoyiannis DP . Risk factors for the

development of invasive fungal infection in allogeneic blood and marrow transplant recipients. _Transplant Infect Dis_ 2002; 4: 3–9. Article  CAS  Google Scholar  * Marr KA, Crippa F,

Leisenring W et al. Itraconazole _versus_ fluconazole for prevention of fungal infections in allogeneic stem cell transplant patients. _Blood_ 2004; 103: 1527–1533. Article  CAS  Google

Scholar  * Herbrecht R, Denning DW, Patterson TF et al. Voriconazole _versus_ amphotericin B for primary therapy of invasive aspergillosis. _N Engl J Med_ 2002; 347: 408–415. Article  CAS 

Google Scholar  * Bacci A, Montagnoli C, Perruccio K et al. Dendritic cells pulsed with fungal RNA induce protective immunity to _Candida albicans_ in hematopoietic transplantation. _J

Immunol_ 2002; 168: 2904–2913. Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS This study was supported by Blood Disease Research Foundation in Finland. AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland E Jantunen, A Nihtinen, L Volin, E Juvonen, T Parkkali, T Ruutu & V-J Anttila

* Department of Medicine, Kuopio University Hospital, Kuopio, Finland E Jantunen Authors * E Jantunen View author publications You can also search for this author inPubMed Google Scholar * A

Nihtinen View author publications You can also search for this author inPubMed Google Scholar * L Volin View author publications You can also search for this author inPubMed Google Scholar

* E Juvonen View author publications You can also search for this author inPubMed Google Scholar * T Parkkali View author publications You can also search for this author inPubMed Google

Scholar * T Ruutu View author publications You can also search for this author inPubMed Google Scholar * V-J Anttila View author publications You can also search for this author inPubMed 

Google Scholar CORRESPONDING AUTHOR Correspondence to E Jantunen. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Jantunen, E., Nihtinen, A., Volin, L.

_et al._ Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis. _Bone Marrow Transplant_ 34, 891–895 (2004).

https://doi.org/10.1038/sj.bmt.1704662 Download citation * Received: 24 March 2004 * Accepted: 13 June 2004 * Published: 02 November 2004 * Issue Date: 01 November 2004 * DOI:

https://doi.org/10.1038/sj.bmt.1704662 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * candidaemia * allogeneic stem cell transplantation *

treatment, outcome